This year ARVO is launching a unique meeting — Bench to Bedside (B2B) — to educate vision scientists on how to advance translational ideas to clinically applied products. This meeting will encourage and foster an innovation mindset amongst eye and vision scientists.

The new B2B program, which will be geared toward the pipeline's early stage, will provide companies with an opportunity to share the trials and tribulations of taking a new discovery to the market with researchers from across the globe. The event will include opportunities for interaction between innovators and venture capitalists, including education on how to obtain funding and enter the beginning and middle phases of clinical trials. Additionally, attendees will receive guidance on technology transfer, patents and regulatory concerns. The program will include a mix of accepted and invited presentations, eye pitch submissions to a panel of experts and other interactive and networking formats.

Bench to Bedside in action

As we gear up for the 2021 Bench to Bedside (B2B) meeting, we invite you to join B2B program committee member Dr. Cheryl Rowe-Rendleman as she sits down with Susan Washer, CEO and president of Applied Genetics Technology Corporation, to discuss how she led an academic startup to become a $150 million public company with four clinical development programs and six early-stage clinical trials. Watch the video